Proscia Launches AI-Powered Digital Pathology Solution
Proscia, a provider of digital pathology software, released DermAI, the first in its series of AI applications that advance the practice of pathology. A module on Proscia’s Concentriq Platform, DermAI leverages deep learning to pre-screen and classify skin biopsies to help reduce diagnostic errors and improve laboratory quality and efficiency as the number of medical professionals entering the field of pathology continues to decline.
The standard of care for diagnosing the 25 million skin biopsies taken in the US every year has been based on a pathologist’s interpretation of patterns in tissue using a microscope. Proscia’s DermAI uses deep learning to read and classify hundreds of variants of skin diseases.
Proscia trained and tested the DermAI algorithm using patient biopsies from leading academic and commercial derm laboratories including Cockerell Dermatopathology, Dermatopathology Laboratory of Central States, The University of Florida, and Thomas Jefferson University Hospital. This multi-site study successfully validated the performance of DermAI using over 20,000 patient biopsy slides. Proscia intends to submit DermAI to the FDA for review to use in clinical diagnosis.
To learn more visit www.proscia.com.
Final ENLIVEN Trial Results Confirm Long-Term Benefit of Turalio in Tenosynovial Giant Cell Tumor
July 9th 2025In final data from the Phase III ENLIVEN study, Turalio (pexidartinib) demonstrated durable tumor responses and a consistent safety profile in patients with symptomatic TGCT not amenable to surgery.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
Effect of AI/ML, Real World Evidence and Master Protocols on Trial Success
July 7th 2025How the application of artificial intelligence, broader use of real-world evidence, decentralized clinical trials, master protocols, and risk-based quality monitoring, together with strong ethical oversight and increased collaboration, are contributing to better healthcare delivery and strengthening the role of clinical research in driving global health progress.
